New formulation of ibuprofen on absorption-rate: A comparative bioavailability study in healthy volunteers. 2019

Yasaman Moghadamnia, and Sohrab Kazemi, and Boshra Rezaee, and Mehrdad Rafati-Rahimzadeh, and Soheil Ebrahimpour, and Fahimeh Aghapour
Alzahra University, Tehran, Iran.

BACKGROUND Enteric-coated capsules are solid dosage forms which are designed to bypass the stomach and release the drug in the small intestine. This study was done to compare pharmacokinetics of ibuprofen tablet and ibuprofen as enteric-coated capsule using sodium alginate beads. METHODS A crossover randomized study was performed on 12 healthy volunteers receiving a single dose of regular ibuprofen tablet (200 mg) and enteric-coated capsule (200 mg). The washout time between the periods was one month. Pharmacokinetic and pharmacodynamic blood samples were collected for 16 hours following treatment. High-performance liquid chromatography (HPLC) method used the following specifications: C18 column with 4.6 mm diameter & 25 mm length, the fluorescent detector of excitation and emission wavelengths were 224 and 290 nm, respectively. RESULTS After a single oral dose of ibuprofen formulations, the median times to maximum concentration were 60 and 240 minutes in ibuprofen tablet (200 mg) and enteric-coated capsule, respectively. The maximum levels for the participants receiving ibuprofen tablet and enteric-coated capsule were 11.71±1.3 and 10.32±4.19 µg/mL, respectively. The pharmacokinetic (PK) modeling data showed the area under curve (AUC) to be 61.51 hours & 86.62 hours for the group receiving the tablet and the capsule, respectively. CONCLUSIONS According to the results, in is concluded that enteric coating may delay the onset of ibuprofen effect and increases the duration of action. This formulation has advantages over the conventional drug delivery systems as it lengthens the dosing intervals and also increases patient compliance for chronic pain.

UI MeSH Term Description Entries

Related Publications

Yasaman Moghadamnia, and Sohrab Kazemi, and Boshra Rezaee, and Mehrdad Rafati-Rahimzadeh, and Soheil Ebrahimpour, and Fahimeh Aghapour
July 2003, Current therapeutic research, clinical and experimental,
Yasaman Moghadamnia, and Sohrab Kazemi, and Boshra Rezaee, and Mehrdad Rafati-Rahimzadeh, and Soheil Ebrahimpour, and Fahimeh Aghapour
August 2019, Clinical therapeutics,
Yasaman Moghadamnia, and Sohrab Kazemi, and Boshra Rezaee, and Mehrdad Rafati-Rahimzadeh, and Soheil Ebrahimpour, and Fahimeh Aghapour
June 2008, International journal of clinical pharmacology and therapeutics,
Yasaman Moghadamnia, and Sohrab Kazemi, and Boshra Rezaee, and Mehrdad Rafati-Rahimzadeh, and Soheil Ebrahimpour, and Fahimeh Aghapour
January 2007, Arzneimittel-Forschung,
Yasaman Moghadamnia, and Sohrab Kazemi, and Boshra Rezaee, and Mehrdad Rafati-Rahimzadeh, and Soheil Ebrahimpour, and Fahimeh Aghapour
January 2006, Arzneimittel-Forschung,
Yasaman Moghadamnia, and Sohrab Kazemi, and Boshra Rezaee, and Mehrdad Rafati-Rahimzadeh, and Soheil Ebrahimpour, and Fahimeh Aghapour
January 1997, European journal of clinical pharmacology,
Yasaman Moghadamnia, and Sohrab Kazemi, and Boshra Rezaee, and Mehrdad Rafati-Rahimzadeh, and Soheil Ebrahimpour, and Fahimeh Aghapour
March 1995, Calcified tissue international,
Yasaman Moghadamnia, and Sohrab Kazemi, and Boshra Rezaee, and Mehrdad Rafati-Rahimzadeh, and Soheil Ebrahimpour, and Fahimeh Aghapour
January 1990, European journal of clinical pharmacology,
Yasaman Moghadamnia, and Sohrab Kazemi, and Boshra Rezaee, and Mehrdad Rafati-Rahimzadeh, and Soheil Ebrahimpour, and Fahimeh Aghapour
January 1997, Chirality,
Yasaman Moghadamnia, and Sohrab Kazemi, and Boshra Rezaee, and Mehrdad Rafati-Rahimzadeh, and Soheil Ebrahimpour, and Fahimeh Aghapour
January 2009, Arzneimittel-Forschung,
Copied contents to your clipboard!